Mitochondrial defects associated with β-alanine toxicity: relevance to hyper-beta-alaninemia
- 477 Downloads
Hyper-beta-alaninemia is a rare metabolic condition that results in elevated plasma and urinary β-alanine levels and is characterized by neurotoxicity, hypotonia, and respiratory distress. It has been proposed that at least some of the symptoms are caused by oxidative stress; however, only limited information is available on the mechanism of reactive oxygen species generation. The present study examines the hypothesis that β-alanine reduces cellular levels of taurine, which are required for normal respiratory chain function; cellular taurine depletion is known to reduce respiratory function and elevate mitochondrial superoxide generation. To test the taurine hypothesis, isolated neonatal rat cardiomyocytes and mouse embryonic fibroblasts were incubated with medium lacking or containing β-alanine. β-alanine treatment led to mitochondrial superoxide accumulation in conjunction with a decrease in oxygen consumption. The defect in β-alanine-mediated respiratory function was detected in permeabilized cells exposed to glutamate/malate but not in cells utilizing succinate, suggesting that β-alanine leads to impaired complex I activity. Taurine treatment limited mitochondrial superoxide generation, supporting a role for taurine in maintaining complex I activity. Also affected by taurine is mitochondrial morphology, as β-alanine-treated fibroblasts undergo fragmentation, a sign of unhealthy mitochondria that is reversed by taurine treatment. If left unaltered, β-alanine-treated fibroblasts also undergo mitochondrial apoptosis, as evidenced by activation of caspases 3 and 9 and the initiation of the mitochondrial permeability transition. Together, these data show that β-alanine mediates changes that reduce ATP generation and enhance oxidative stress, factors that contribute to heart failure.
KeywordsElectron transport chain Oxidative stress Respiration Taurine Mitochondrial fragmentation Apoptosis
We appreciate the financial support of Taisho Pharmaceutical Co. and the intellectual input of our deceased colleague, Dr. Junichi Azuma, Osaka, Japan.
- 6.Gibson MK, Jakobs C (2001) Disorder of β- and γ-amino acids in free and peptide-linked forms. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular basis of inherited disease. McGraw Hill, New York, pp 2079–2105Google Scholar
- 10.Schaffer SW, Shimada-Takaura K, Jong CJ, Ito T, Takahashi K (2016) Impaired energy metabolism of the taurine-deficient heart. Amino Acids 7:1–10Google Scholar
- 11.Grishko V, Pastukh V, Solodushko V, Gillespie M, Azuma J, Schaffer S (2003) Apoptotic cascade initiated by angiotensin II in neonatal cardiomyocytes: role of DNA damage. Am J Physiol 285:H2364–H2372Google Scholar
- 17.Jong CJ, Ito T, Mozaffari M, Azuma J, Schaffer S (2010) Effects of β-alanine treatment on mitochondrial taurine level and 5-taurinomethyluridine content. J Biomed Sci 17(S1):525–532Google Scholar
- 28.Ramila KC, Jong CJ, Pastukh V, Ito T, Azuma J, Schaffer SW (2015) Role of protein phosphorylation in excitation-contraction coupling in taurine deficient hearts. Am J Physiol 308(3):H232–H239Google Scholar